By Katherine Hamilton
Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq.
The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year.
The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday.
Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said.
The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
April 01, 2025 15:15 ET (19:15 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.